Reduced risk of hepatocellular carcinoma after interferon therapy in aged patients with chronic hepatitis C is limited to sustained virological responders

Journal of Viral Hepatitis

Volumn 17, Issue 3, 2010, Pages 185-191

  Imai, Y ^a   Tamura, S ^b   Tanaka, H ^c   Hiramatsu, N ^d   Kiso, S ^d   Doi, Y ^e   Inada, M ^f   Nagase, T ^g   Kitada, T ^h   Imanaka, K ⁱ   Fukuda, K ^a   Takehara, T ^d   Kasahara, A ^d   Hayashi, N ^d  

^a IKEDA MUNICIPAL HOSPITAL   (Japan)

^b Minoh City Hospital   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d OSAKA UNIVERSITY   (Japan)

^e Otemae Hospital   (Japan)

^f TOYONAKA MUNICIPAL HOSPITAL   (Japan)

^g Suita Municipal Hospital   (Japan)

^h Itami Municipal Hospital   (Japan)

ⁱ Osaka Center for Cancer and Cardiovascular Diseases   (Japan)

Author keywords

Aged patients; Chronic hepatitis C; Hepatocellular carcinoma; Interferon; Sustained virological response

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; AGED; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; FEMALE; HEPATITIS C; HISTOLOGY; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK REDUCTION; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 75149195296     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01163.x     Document Type: Article

References (32)

1. Yoshizawa H. Hepatocellular carcinoma associated with hepatitis C virus infection in Japan: projection to other countries in the foreseeable future. Oncology 2002 62 (Suppl. 1 8 17.
2. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention. Asian Pac J Cancer Prev 2005 6: 44 50.
3. Tanaka H, Tsukuma H. Characteristics of Japanese patients with liver cancer-epidemiological study based on a comparison between male and female patients. Hepatol Res 2002 24: S11 S20.
4. Tanaka Y, Kurbanov F, Mano S et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology 2006 130: 703 714.
5. Tanaka H, Imai Y, Hiramatsu N et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008 148: 820 826.
6. Tanaka H, Hiyama T, Tsukuma H et al. Prevalence of second generation antibody to hepatitis C virus among voluntary blood donors in Osaka, Japan. Cancer Causes Control 1994 5: 409 413.
7. Tanaka H, Tsukuma H, Kasahara A et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000 87: 741 749.
8. Yoshida H, Arakawa Y, Sata M et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002 123: 483 491.
9. Kasahara A, Tanaka H, Okanoue T et al. Interferon treatment improves survival in chronic hepatitis C patients showing biochemical as well as virological responses by preventing liver-related death. J Viral Hepat 2004 11: 148 156.
10. Imai Y, Kasahara A, Tanaka H et al. Interferon therapy for aged patients with chronic hepatitis C: improved survival in patients exhibiting a biochemical response. J Gastroenterol 2004 39: 1069 1077. (Pubitemid 39618790)
11. Mazzella G, Accogli E, Sottili S et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996 24: 141 147.
12. Fattovich G, Giustina G, Degos F et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol 1997 27: 201 205.
13. Imai Y, Kawata S, Tamura S et al. Relationship of interferon therapy and hepatocellular carcinoma in patients with chronic heaptitis C. Ann Intern Med 1998 129: 94 99.
14. Nishiguchi S, Kuroki T, Nakatanl S et al. Randomised trial of effects if interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995 346: 1051 1055.
15. Kasahara A, Hayashi N, Mochizuki K et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology 1998 27: 1394 1402.
16. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999 131: 174 181.
17. Ikeda K, Saitoh S, Arase Y et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 1999 29: 1124 1130.
18. Kurokawa M, Hiramatsu N, Oze T et al. Effect of interferon alpha-2b plus ribavirin therapy on incidence of hepatocellular carcinoma in patients with chronic hepatitis. Hepatol Res 2009 39: 432 438.
19. Manns MP, McHutchison JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 358: 958 965.
20. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347: 975 982.
21. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006 355: 2444 2451.
22. Arase Y, Ikeda K, Suzuki F et al. Prolonged-interferon therapy reduces hepatocarcinogenesis in aged-patients with chronic hepatitis C. J Med Virol 2007 79: 1095 1102.
23. Di Bisceglie AM, Shiffman ML, Everson GT et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008 359: 2429 2441.
24. Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009 136: 138 148.
25. Kato N, Yokosuka O, Omata M, Hosoda K, Ohto M. Detection of hepatic C virus ribonucleic acid in the serum by amplification with polymers chain reaction. J Clin Invest 1990 86: 1764 1767.
26. Murakami R, Tsukuma H, Ubukata T et al. Estimation of validity of mass screening program for gastric cancer in Osaka, Japan. Cancer 1990 65: 1255 1260.
27. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Sheuer PJ. Classification of chronic hepatitis: grading and staging. Hepatology 1994 19: 1513 1520.
28. Knodell RG, Ishak KG, Black WC et al. Formulation and application of numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981 1: 431 435.
29. Ikeda K, Saitoh S, Koida I et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993 18: 47 53.
30. Moriya K, Fujie H, Shintani Y et al. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nat Med 1998 4: 1065 1067.
31. Moriya K, Nakagawa K, Santa T et al. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001 61: 4365 4370.
32. Makiyama A, Itoh Y, Kasahara A et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after sustained response to interferon therapy. Cancer 2004 101: 1616 1622.